Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of S086 versus Entresto in chronic heart failure with reduced ejection fraction
ChiCTR2200061583Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing S086 tablets group with Sacubitril/valsartan group (2 arms). Primary endpoint: Left ventricular ejection fraction. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
S086sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2200061583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061583.